BeiGene, founded in 2010 by John V. Oyler and Xiaodong Wang, is a global biotechnology company specializing in the development of oncology treatments. It is headquartered in Cambridge, Massachusetts, with significant operations in Beijing, China, and Basel, Switzerland. The company has a strong global presence, with offices on six continents and in over 45 countries. BeiGene focuses on creating innovative cancer therapies, including notable drugs like tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton’s tyrosine kinase inhibitor. The company aims to address various forms of cancer through a broad pipeline of products and research initiatives. BeiGene has filed numerous patents related to clusters of differentiation, transcription factors, and immune system treatments. In recent developments, the company announced its rebranding to BeOne Medicines and redomiciled to Basel, Switzerland, with a U.S. subsidiary name change to BeOne Medicines USA, Inc. This rebranding highlights its dedication to partnering globally to improve cancer patient outcomes. BeiGene’s corporate headquarters is located at 55 Cambridge Parkway, Suite 700W, Cambridge, MA, with a major operational base in Beijing, China at 30 Science Park Road, Zhongguancun Life Science Park.